| Gene symbol | PTGS2 | Synonyms | COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2, hCox-2 | Type of gene | protein-coding |
| Chromosome | 1 | Map location | 1q31.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PertOrg | ||||
| Description | prostaglandin-endoperoxide synthase 2 | ||||
| Gene symbol | TGFB1 | Synonyms | CED, DPD1, IBDIMDE, LAP, TGF-beta1, TGFB, TGFbeta | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | transforming growth factor beta 1 | ||||
| GTO ID | GTC2660 |
| Trial ID | NCT04844983 |
| Disease | Squamous Cell Carcinoma |
| Altered gene | TGFB1|PTGS2 |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | STP705|COTSIRANIB |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Patients With Cutaneous Squamous Cell Carcinoma in Situ (isSCC) |
| Year | 2021 |
| Country | United States |
| Company sponsor | Sirnaomics |
| Other ID(s) | SRN-705-008 |
| Vector information | |||
|
|||
| Cohort1: STP705_dose level 1 | |||||||
|
|||||||
| Cohort2: STP705_dose level 2 | |||||||
|
|||||||
| Cohort3: STP705_dose level 3 | |||||||
|
|||||||
| Cohort4: Placebo | |||||||
|
|||||||